

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

Provision of Interventional Oncology Services in the United Kingdom: Pilot Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016631
Article Type:	Research
Date Submitted by the Author:	18-Apr-2017
Complete List of Authors:	Zhong, Jim; St. James's University Hospital, Clinical and Interventional Radiology Atiiga, Peter; St. James's University Hospital, Clinical and Interventional Radiology Alcorn, Des; Glasgow Royal Infirmary, Interventional Radiology Kay, David; Glasgow Royal Infirmary, Interventional Radiology Illing, Rowland; University College London Hospitals NHS Foundation Trust, Interventional Radiology Breen, David; University Hospital Southampton, Radiology Railton, Nicholas; Mid Essex Hospital Services NHS Trust, Interventional Radiology McCafferty, Ian; The Queen Elizabeth Hospital Birmingham, Interventional Radiology Haslem, Philip; Freeman Hospital, Interventional Radiology Wah, Tze; St. James's University Hospital, Clinical and Interventional Radiology
Primary Subject Heading:	Radiology and imaging
Secondary Subject Heading:	Oncology, Diagnostics, Medical education and training
Keywords:	Interventional radiology < RADIOLOGY & IMAGING, Adult oncology < ONCOLOGY, Cancer pain < ONCOLOGY, Gastrointestinal tumours < ONCOLOGY, Hepatobiliary tumours < ONCOLOGY, Kidney tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1 Provision of Interventional Oncology Services in the United Kingdom: Pilot Study

3 Author List (in order):

- 4 1. Dr Jim Zhong (JZ), Radiology Registrar, Department of Clinical and Interventional Radiology,
5 Institute of Oncology, St James University Hospital, Leeds, LS9 7TF, United Kingdom.
- 6 2. Dr Peter Atiiga [1], Foundation Year 2 Doctor, Department of Clinical and Interventional
7 Radiology, Institute of Oncology, St James University Hospital, Leeds, LS9 7TF, United
8 Kingdom.
- 9 3. *Dr Des J Alcorn (DJA), Consultant Interventional Radiologist, Glasgow Royal Infirmary,
10 Interventional Radiology, Glasgow, G4 0SF, United Kingdom
- 11 4. *Dr David Kay (DK), Consultant Interventional Radiologist, Glasgow Royal Infirmary,
12 Interventional Radiology, Glasgow, G4 0SF, United Kingdom
- 13 5. *Dr Rowland Illing (RI), Consultant Interventional Radiologist, University College Hospital,
14 Interventional Radiology, London, NW1 2BU, United Kingdom
- 15 6. *Dr David Breen (DB), Consultant Interventional Radiologist, Southampton University
16 Hospitals, Radiology, Southampton, United Kingdom
- 17 7. *Dr Nicholas Railton (N R), Consultant Interventional Radiologist, Mid Essex Hospital NHS
18 trust, Interventional Radiology, Chelmsford, United Kingdom
- 19 8. *Dr Ian J McCafferty (IJM), Consultant Interventional Radiologist, The Queen Elizabeth
20 Hospital Birmingham, University Hospital Birmingham NHS Trust, Dept. of Radiology,
21 Birmingham, B15 2TH, United Kingdom.
- 22 9. *Dr Philip J Haslam (PJH), Consultant Interventional Radiologist, Freeman Hospital,
23 Interventional Radiology, Newcastle-upon-Tyne, NE7 7DN, United Kingdom
- 24 10. *Dr Tze Min Wah (TMW), Clinical Lead for LTHT IO Programme, IOUK Chair (British Society of
25 Interventional Radiology), Consultant Radiologist & Honorary Clinical Associate Professor
26 (University of Leeds), Department of Clinical and Interventional Radiology, Institute of
27 Oncology, St James University Hospital, Leeds, LS9 7TF, United Kingdom.

28 *All members of the Interventional Oncology United Kingdom (IOUK) group, a specialist interest
29 group of the British Society of Interventional Radiology (BSIR).

1
2 303
4 31 **Corresponding author:**5
6 32 Dr Jim Zhong7
8 33 Department of Clinical and Interventional Radiology9
10 34 Institute of Oncology11
12 35 St James University Hospital13
14 36 Leeds, LS9 7TF, United Kingdom.15
16 37 E-mail address: j.zhong.edinburgh@gmail.com17
18 38 Mobile: 0741195280819
20 3921
22 40 **Keywords:**23
24 41 Interventional oncology25
26 42 Radiology27
28 43 Ablation29
30 44 Networks31
32 4533
34 46 **Word Count (Excluding title page and abstract):**35
36 47 270437
38 4839
40 49 **Contributorship Statement**41
42 50 Dr Jim Zhong (JZ) was also involved with designing the initial study concept, initial literature
43
44 51 search, designing the survey and questionnaire layout, all data collection and analysis, writing up
45
46 52 the manuscript and revising the manuscript in discussion with other authors. He has prepared the
47
48 53 manuscript for publication.49
50 54 Dr Peter Atiiga (P A) was also involved with designing the survey and questionnaire layout, the
51
52 55 data collection and revising the manuscript in discussion with other authors.53
54 56 Dr Des J Alcorn (DJA) was also involved with finalizing the initial study concept, reviewing and
55
56 57 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
57
58 58 manuscript for publication in discussion with the other authors.
59
60

1
2 59 Dr David Kay (DK) was also involved with finalizing the initial study concept, reviewing and
3
4 60 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
5
6 61 manuscript for publication in discussion with the other authors.
7
8 62 Dr Rowland Illing (RI) was also involved with finalizing the initial study concept, reviewing and
9
10 63 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
11
12 64 manuscript for publication in discussion with the other authors.
13
14 65 Dr David Breen (DB) was also involved with finalizing the initial study concept, reviewing and
15
16 66 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
17
18 67 manuscript for publication in discussion with the other authors.
19
20 68 Dr Nicholas Railton (N R) was also involved with finalizing the initial study concept, reviewing and
21
22 69 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
23
24 70 manuscript for publication in discussion with the other authors.
25
26 71 Dr Ian J McCafferty (IJM) was also involved with finalizing the initial study concept, reviewing and
27
28 72 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
29
30 73 manuscript for publication in discussion with the other authors.
31
32 74 Dr Philip J Haslam (PJH) was also involved with finalizing the initial study concept, reviewing and
33
34 75 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
35
36 76 manuscript for publication in discussion with the other authors.
37
38 77 Dr Tze Min Wah (TMW) was also involved with designing the initial study concept, approving the
39
40 78 survey and questionnaire layout, reviewing the results and analysis, and revising the manuscript in
41
42 79 discussion with other authors and approving the manuscript for publication in discussion with the
43
44 80 other authors.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

81 **Abstract**

82 **Objective:**

83 To map out the current provision of interventional oncology (IO) services in the United Kingdom.

84

85 **Design:**

86 Multi-centre survey

87

88 **Setting:**

89 All NHS Trusts in England and Scottish, Welsh and Northern Ireland health boards.

90

91 **Participants:**

92 Interventional Radiology departments in all NHS trusts/ health boards in the United Kingdom.

93

94 **Results**

95 A total of 179 NHS trusts/health boards were contacted. We received 100% response rate. 144
96 trusts (80%) provided IO services or had a formal pathway of referral in place for patients to a
97 recipient trust. 21 trusts (12%) had plans to provide an IO service or formal referral pathway in the
98 next 12 months only. 14 trusts (8%) did not have a pathway of referral and no plans to implement
99 one.

100 70 trusts (39%) offered both supportive and disease-modifying procedures. 73 trusts (41%)
101 provided only supportive procedures. Of these, 43 (59%) had a referral pathway for disease-
102 modifying IO procedures, either from a regional cancer network or through interventional radiology
103 networks. 14 (8%) did not have a pathway of referral and no plans to implement one.

104

105 **Conclusion**

106 The provision of IO services in the UK is promising however collaborative networks are necessary
107 to ensure disease-modifying IO procedures are made accessible to all patients and to facilitate
108 larger registry data for research with commissioning of new services.

109

1
2 110 **Article Summary**

3
4 111 **Strengths and limitations of this study**

- 5
6 112 • 100% response rate from 179 Acute NHS Trusts and Health Boards throughout the United
7
8 113 Kingdom
- 9
10 114 • Provides comprehensive map of Interventional Oncology (IO) Services throughout the UK to
11
12 115 allow for more integrated cancer pathways on a national level.
- 13
14 116 • Map of the provision and geographic variation in disease modifying procedures such as tumour
15
16 117 ablation, which will allow for future planning of new IO services.
- 17
18 118 • Identifies types of supportive IO treatments, which are less routinely available apart from in
19
20 119 larger tertiary centres and therefore highlights areas to target for IO training.
- 21
22 120 • Limitations include those inherent to survey/ questionnaire format, such as subjective bias.
23
24
25
26
27
28
29
30
31 124

125 Introduction

126 More than 1-in-3 people will develop cancer in their lifetime[1]. Since the NHS Cancer Plan in
127 2000, the Department of Health has strived to improve diagnosis and treatment[1]. As part of the
128 NHS plans to deliver world-class cancer services, there is a drive to achieve better outcomes by
129 ensuring all patients have access to the best treatments available[2]. Wide variation remains in
130 performance across the country with major differences in access to cancer services[1].

131

132 Interventional oncology (IO), image guided procedures used to diagnose and treat oncological
133 patients, is fast becoming the four pillar of oncological care alongside medical, surgical and
134 radiation oncology. The Royal College of Radiologists have set out best practice guidance for the
135 incorporation of interventional oncology into all cancer services nationally[3]. There remains a
136 significant shortage of interventional radiologists, who are the primary contributors towards IO, with
137 almost half of services in England unable to provide a local or networked out of hours access to
138 Interventional Radiology (IR)[4]. Undoubtedly this shortfall will have consequences on the provision
139 of elective IO services in the UK and potentially affect patient care through limitations to access.

140 The current provision of Interventional Oncology services throughout the UK is unknown, therefore
141 NHS commissioners are unable to realistically factor IO into national cancer pathways as evident
142 in a previous Department of Health publication[1] which did not acknowledge IO as a treatment
143 option for patients out with surgery, chemotherapy and radiotherapy.

144

145 The primary objective of this national survey was to map out the current provision of interventional
146 oncology services in the UK. We also sought to uncover formal patient referral pathways, the types
147 of IO procedures offered and any limitations to providing IO. Ultimately, we aim to develop IO
148 networks and improve access to these treatments for cancer patients.

149

150 The survey was designed and undertaken in collaboration with the Interventional Oncology United
151 Kingdom (IOUK) group, a specialist interest group of the British Society of Interventional Radiology
152 (BSIR).

153

1
2 154 **Method**

3
4 155 No research ethics committee approval was required for this service redesign data-gathering
5
6 156 project. No patient identifiable data was gathered.

7
8 157

9
10 158 All NHS Foundation Trusts in England[5] and all health boards in Scotland, Wales and Northern
11
12 159 Ireland were contacted by email (see supplementary material). This was followed by a telephone
13
14 160 follow-up of all hospital radiology departments that did not complete the survey within 2 weeks of
15
16 161 the first email being sent out. Telephone follow-up was conducted by a single radiologist (JZ). The
17
18 162 survey could be completed by any of the following: Head of department of radiology/ interventional
19
20 163 radiology, any consultant radiologist (diagnostic or interventional) or superintendent radiographer
21
22 164 who has insight into the local provision of services.

23
24 165

25
26 166 The surveys key points were:

- 27
28 167
 - Are IO procedures offered in the trust?
- 29
30 168
 - If so, are these supportive treatments only or both supportive and disease-modifying?
- 31
32 169
 - We asked about the types of procedures undertaken
- 33
34 170
 - If not, is there an agreed formal pathway to another recipient trust?
- 35
36 171
 - If there was no agreed pathway, was there a plan to provide IO or a pathway in the next 12
- 37
38 172 months?
- 39
40 173
 - What barriers are there to setting up an IO service?

41
42 174

43
44 175 The full survey can be found in the online supplementary file.

45
46 176 Supportive and symptomatic procedures were defined as those providing relief from tumour-
47
48 177 related symptoms but do not modify the underlying malignant disease process and includes
49
50 178 diagnostic tests such as image guided biopsy which 'support' the provision of definitive
51
52 179 treatment[3]. Disease modifying procedures were defined as those where the intent is to modify
53
54 180 malignant progression and/or modify the prognosis and includes image-guided ablation, trans-
55
56 181 arterial chemoembolisation (TACE) and selective internal radiation therapy (SIRT).

57
58 182

1 183 Following the initial survey we followed up all trusts/ health boards which only offered supportive
2
3 184 treatments to see if there were formal referral pathways for disease-modifying procedures.

4
5 185 A formal referral pathway was defined as an existing mechanism of referral through a multi-
6
7 186 disciplinary team responsible for the patient, usually through a pre-existing local oncology or
8
9 187 radiology network.

10
11 188

12 13 189 **Results**

14
15 190 A total of 179 NHS trusts or health boards were contacted throughout the United Kingdom. We
16
17 191 received 100% response rate. The responses came from consultant interventional and diagnostic
18
19 192 radiologists and superintendent radiographers who had insight into the local provision of services.

20
21 193 144 trusts (80%) provided IO services or had a formal pathway of referral in place for patients to a
22
23 194 recipient trust (Figure 1). 21 trusts (12%) had plans to provide an IO service or formal referral
24
25 195 pathway in the next 12 months only. 14 trusts (8%) did not have a pathway of referral and no plans
26
27 196 to implement one. 70 trusts (39%) offered both supportive and disease-modifying procedures on
28
29 197 site (Figure 2). 73 trusts (41%) provided only supportive procedures on site. One trust had a
30
31 198 formal referral pathway for supportive IO. Only 19 (11%) institutions had an interventional oncology
32
33 199 lead.

34
35 200

36
37 201 The number of trusts providing each supportive/ symptomatic IO procedure and disease-modifying
38
39 202 procedure are shown in table 1 and table 2. These are represented in graphical form in Figure 3.

40
41 203 Figure 4 and 5 show the maps of the trusts providing each type of disease-modifying procedure.

42
43 204

44
45 205 For England only, a total of 153 NHS Foundation trusts in England were contacted. 127 (83%)
46
47 206 trusts provided IO services or had a formal pathway of referral to another agreed recipient trust for
48
49 207 IO procedures (Figure 1). Out of the 26 that did not have a formal referral pathway, 21 (14%) trusts
50
51 208 had plans to provide an IO service or formal referral pathway for patients to have IO at another
52
53 209 trust within the next 12 months. 5 (3%) trusts did not have a pathway and had no plans of providing
54
55 210 IO or a referral pathway in the next 12 months (Figure 1). 57 out of 127 (45%) trusts providing IO
56
57
58
59
60

1 211 offered both supportive and disease modifying procedures (Figure 2). 70 out of 127 (55%)
2
3 212 provided only supportive procedures.
4

5 213
6

7 214 For Scotland, 10 out of 14 health boards provided IO or had a formal pathway of referral to a
8
9 215 specialist hospital in another health board (Glasgow or Edinburgh). Of these, 8 health boards
10
11 216 provided both supportive and disease-modifying IO while 2 provided only supportive IO. 4 health
12
13 217 boards (29%) did not provide IO and did not have plans to provide a pathway in the next 12
14
15 218 months.
16

17 219
18

19 220 For Wales, 6 out of 7 health boards (86%) provided IO or had a referral pathway in place. 4 Welsh
20
21 221 health boards (57%) provided both types of IO, one health board provided only supportive IO and
22
23 222 one had a formal referral pathway. One Welsh health board did not offer IO or have a referral
24
25 223 pathway implemented in the next 12 months.
26

27 224 Only 1 out of 5 health boards in Northern Ireland (Belfast Health and Social Care Trust) provided
28
29 225 IO (both types).
30

31 226
32

33 227 Out of the 70 English NHS trusts and 3 Scottish/ Welsh Health Boards, which provided only
34
35 228 supportive IO, 43 trusts (59%) had a referral pathway to another hospital/ trust for disease-
36
37 229 modifying IO procedures. This was from a local regional cancer network referral initiated following
38
39 230 a formal discussion at the multi-disciplinary team meeting.
40

41 231
42

43 232 The most common barriers to providing disease-modifying IO were insufficient funding, lack of
44
45 233 staff, lack of support from other non-radiology clinicians, having a pathway already in place and
46
47 234 problems with recruitment into IR.
48

49 235
50

51 236 **Discussion**

52 237 Overall, the provision of IO in the UK is promising. Based on the Royal College of Radiologists
53
54 238 definition of 'supportive' IO[1], this encompasses many routine procedures that can be carried out
55
56 239 by diagnostic radiologists which is reflected in the excellent availability of these procedures
57
58
59
60

1
2 240 throughout the UK. Beyond basic image-guided drainage procedures, the provision of specialist
3
4 241 vascular, gastro-intestinal or biliary 'symptomatic' intervention is less routinely available apart from
5
6 242 in the larger tertiary centers which were also providing disease-modifying IO. This highlights
7
8 243 important areas to target for radiology and IO training.
9

10 244

11 245 Given the vital role of IR in the management of critically ill patients, the comprehensive provision of
12
13 246 supportive IO in most parts of the UK reflects the drive to train more radiologists with basic
14
15 247 interventional skills, which are also transferrable to IO[6]. We acknowledge that providing out of
16
17 248 hours IR is not directly related to IO however it will allow for 'supportive' IO to be routinely available
18
19 249 which encompasses many routine procedures that are the backbone of IO, whereas disease-
20
21 250 modifying treatments can be centralized as part of the current NHS model for cancer services[7].
22
23

24 251 There are still NHS trusts/ boards, most noticeably in rural Scotland and Northern Ireland where
25
26 252 provision of IO services appear limited and linking up with neighboring hospitals to set up formal
27
28 253 pathways would be a first step to improving access for patients to disease-modifying IO. What
29
30 254 remains unclear is what the current demand for IO services are generally but particularly in these
31
32 255 rural regions, as we have no data to suggest current arrangements are sub-optimal. It would not be
33
34 256 necessary or appropriate for all providers to liaise with IO services, and these should be facilitated
35
36 257 through regional cancer networks with more integrated pathways of care[7]. Currently there
37
38 258 appears to be 136 out of 153 acute NHS trusts in England, which are listed to offer acute oncology
39
40 259 services[8]. Further work is required to elucidate whether there is any discrepancy in the regional
41
42 260 demand and supply of disease-modifying IO.
43

44 261

45
46 262 Of the trusts that only offered supportive IO, 59% had a formal referral pathway to another centre
47
48 263 for disease-modifying IO. The perceived barriers from these trusts to starting up elective disease-
49
50 264 modifying services stemmed from shortfalls in funding, staffing and support from other specialties.

51
52 265 With tertiary centres undertaking much higher volumes of disease modifying IO procedures, some
53
54 266 smaller district general hospitals felt unsupported in starting up their own service, from financial
55
56 267 considerations when purchasing the equipment to garnering support from allied specialties such as
57
58 268 surgery and oncology. This is an important point as it highlights the need for greater awareness of
59
60

1
2 269 the role of the interventional radiologist in oncology care and we must strive to work even closer
3
4 270 with oncologists given the new evidence suggesting the added value of combination therapies and
5
6 271 incorporation of IO procedures into European cancer guidelines[9]. However, with the current
7
8 272 model of centralizing cancer services, these barriers would only be an issue if cancer centers were
9
10 273 unable to provide IO. To improve patient selection for complex IO procedures, interventional
11
12 274 radiologists should have a regular role in multi-disciplinary team meetings. With only 19 institutions
13
14 275 (11%) currently having a formal IO lead clinician, there is a role for dispersed leadership to achieve
15
16 276 structural change in established cancer networks.
17

277

20 278 Local expertise and facilities help determine the IO that is offered. An example is the provision of
21
22 279 disease-modifying IO for the liver, which is centred around the national liver transplant units[10].
23
24 280 The reasons for this are clear given that image-guided tumour ablation, TACE and SIRT are
25
26 281 effective therapies than can be used solely or in combination with chemotherapy or surgery to
27
28 282 improve the outcome of such patients who can be complex and should be managed by multi-
29
30 283 disciplinary teams (MDT) [11 12]. Interventional radiologists must endeavor to participate in MDT
31
32 284 discussions to educate other clinicians on the role of IO in the management of patients and
33
34 285 contribute towards improvement and restructuring of services. This will also open opportunities to
35
36 286 undertake collaborative research that will be higher impact and wider reaching to the oncology
37
38 287 community.
39

288

42 289 The recurrent issue of lack of staffing within IR remains a barrier. Despite the promising provision
43
44 290 of supportive IO, most departments are struggling to cope with the demand for basic vascular,
45
46 291 urological and biliary procedures, necessary to provide a sustainable out of hours service, without
47
48 292 compounding this with additional workload and need for additional training for disease-modifying
49
50 293 IO. Additional need for interventional radiographers and nursing cover for IO services should not
51
52 294 be overlooked either to allow a new service to be introduced.
53

295

56 296 Changes to the delivery of healthcare throughout the UK demands that IO treatments can
57
58 297 demonstrate not only a therapeutic benefit but also cost-effectiveness. For units with a referral
59
60

1
2 298 pathway for disease-modifying IO, there was a common theme that this set-up was more cost
3
4 299 effective than starting a service from scratch. Without knowledge of the actual demand for these IO
5
6 300 procedures, there is no answer to this currently, and clinical investigators must incorporate
7
8 301 measures of cost-effectiveness and patient-reported outcomes into large-scale studies to provide
9
10 302 more robust evidence[13]. Even if these IO treatments can be shown to be equally effective
11
12 303 compared with the current standard of care but with significantly less morbidity, then it will allow
13
14 304 the specialty to develop further, however current studies have not offered definitive
15
16 305 conclusions[14]. Building upon the knowledge of these IO networks will allow better registry data
17
18 306 that can be used to derive larger cohorts for future trials and also commissioning of new services.
19
20 307

21
22 308 The limitations of the present study include those inherent in the survey/ questionnaire format such
23
24 309 as the subjective element depending on whether a superintendent radiographer or consultant
25
26 310 radiologist responded given their underlying experience and knowledge of their radiology services
27
28 311 which could impact on the detail of their survey answers. The strengths of the survey include 100%
29
30 312 response rate from 179 acute NHS trusts/ health boards which allowed a comprehensive map of
31
32 313 both supportive and disease-modifying IO procedures offered in the UK that will help direct
33
34 314 radiology/IO training, future planning of new IO services and allow for more integrated cancer
35
36 315 pathways.
37
38 316

39 40 317 **Conclusion**

41
42 318 The provision of IO services in the UK is promising however collaboration and networking is
43
44 319 necessary to ensure disease-modifying IO procedures are made accessible to all patients
45
46 320 throughout the UK and to facilitate larger registry data for research and commissioning of new
47
48 321 services.
49
50 322

51
52 323
53
54
55
56
57
58
59
60

1
2 324 This research received no specific grant from any funding agency in the public, commercial or not-
3
4 325 for-profit sectors.
5
6 326
7
8 327 All authors have completed the ICMJE uniform disclosure form at
9
10 328 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted
11
12 329 work; no financial relationships with any organisations that might have an interest in the submitted
13
14 330 work in the previous three years; no other relationships or activities that could appear to have
15
16 331 influenced the submitted work
17
18 332
19
20 333 Transparency declaration: I affirm that the manuscript is an honest, accurate, and transparent
21
22 334 account of the study being reported; that no important aspects of the study have been omitted; and
23
24 335 that any discrepancies from the study as planned (and, if relevant, registered) have been
25
26 336 explained.
27
28 337
29
30 338 Data sharing: no additional data available.
31
32 339
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 340 **References**

- 3
4 341 1. NHS England Department of Health and Public Health England. Progress in improving
5
6 342 cancer services and outcomes in England. 2015.
- 7
8 343 2. NHS England. Achieving World-Class Cancer Outcomes: Taking the strategy forward. 2016
- 9
10 344 3. Royal College of Radiologists. Interventional oncology: guidance for service delivery. 2013.
11
12 345 http://www.rcr.ac.uk/sites/default/files/publication/RCR%2813%29_IO_0.pdf.
- 13
14 346 4. Centre for Workforce Intelligence. Securing the future workforce supply: clinical radiology
15
16 347 stocktake. In: London: Centre for Workforce Intelligence, ed., 2012.
- 17
18 348 5. UK Government. Transparency data NHS foundation trust directory. 2015.
19
20 349 [https://http://www.gov.uk/government/publications/nhs-foundation-trust-](https://http://www.gov.uk/government/publications/nhs-foundation-trust-directory/nhs-foundation-trust-directory)
21
22 350 [directory/nhs-foundation-trust-directory](https://http://www.gov.uk/government/publications/nhs-foundation-trust-directory/nhs-foundation-trust-directory).
- 23
24 351 6. Royal College of Radiologists. Provision of Interventional Radiology Services. 2013.
25
26 352 [https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR\(](https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR(14)12_POIR.pdf)
27
28 353 [14\)12_POIR.pdf](https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR(14)12_POIR.pdf).
- 29
30 354 7. Independent Cancer Taskforce Cancer Research UK. Achieving World-Class Cancer
31
32 355 Outcomes, A strategy for England 2015-2020. 2015
- 33
34 356 8. National Peer Review Programme. My Cancer Treatment. Secondary My Cancer Treatment.
35
36 357 2016. <http://www.mycancertreatment.nhs.uk/find-your-treatment/>.
- 37
38 358 9. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice
39
40 359 Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal
41
42 360 of the European Society for Medical Oncology / ESMO 2016;**27**(suppl 5):v58-v68 doi:
43
44 361 10.1093/annonc/mdw328[published Online First: Epub Date]].
- 45
46 362 10. NHS Blood and Transplant. Transplant Units in the UK. Secondary Transplant Units in the
47
48 363 UK. 2016. <http://www.odt.nhs.uk/transplantation/transplant-units-in-uk/>.
- 49
50 364 11. Hickey R, Vouche M, Sze DY, et al. Cancer Concepts and Principles: Primer for the
51
52 365 Interventional Oncologist-Part I. Journal of Vascular and Interventional Radiology
- 53
54
55
56
57
58
59
60

- 1
2 366 2013;**24**(8):1157-64 doi: 10.1016/j.jvir.2013.04.024[published Online First: Epub
3
4 367 Date]].
- 5
6 368 12. Hickey R, Vouche M, Sze DY, et al. Cancer Concepts and Principles: Primer for the
7
8 369 Interventional Oncologist-Part II. Journal of Vascular and Interventional Radiology
9
10 370 2013;**24**(8):1167-88 doi: 10.1016/j.jvir.2013.04.023[published Online First: Epub
11
12 371 Date]].
- 13
14 372 13. Franklin JM, GebSKI V, Poston GJ, et al. Clinical trials of interventional oncology-moving
15
16 373 from efficacy to outcomes. Nature reviews. Clinical oncology 2015;**12**(2):93-104 doi:
17
18 374 10.1038/nrclinonc.2014.199[published Online First: Epub Date]].
- 19
20 375 14. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014
21
22 376 update. European urology 2015;**67**(5):913-24 doi:
23
24 377 10.1016/j.eururo.2015.01.005[published Online First: Epub Date]].
- 25
26
27
28
29 378
30 379
31
32 380

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

381 **Figure Legends:**

382 **Figure 1:** UK Map showing the overall provision of interventional oncology (IO) services
383 throughout the UK.

384 **Figure 2:** UK Map showing what types of IO procedures (supportive and/ or disease modifying
385 procedures) are undertaken in each NHS trust/ health board.

386 **Figure 3:** Bar charts showing number of trusts offering: (A) Each type of supportive/symptomatic
387 IO procedure and (B) Each type of disease-modifying IO procedure.

388 **Figure 4:** UK Map showing the provision of ablation services: (A) Renal ablation (B) Liver ablation
389 (C) Bone ablation and (D) Lung ablation.

390 **Figure 5:** UK Map showing the provision of (A) Trans-arterial chemoembolization (TACE) and (B)
391 Selective internal radiation therapy (SIRT).

392

393

394

395

396

397 **Table Legends**

398 **Table 1:** Type of supportive/ symptomatic IO procedure and number of trusts that offer each and
 399 percentage of total number of trusts (n=179).

Type of supportive/ symptomatic IO procedure	Number of trusts	Percentage (%)
Ascitic diversion	39	22
Vena caval stenting	79	44
Enteral tube placement e.g. Radiologically Inserted Gastrostomy (RIG)	81	45
Percutaneous Trans-hepatic Cholangiography (PTC)	84	47
Gastrointestinal stenting	87	49
Vena caval filtration	88	49
Biliary drainage and stenting	118	66
Ureteric stenting	124	69
Central venous catheter	125	70
Image-guided drainage	128	72
Nephrostomy	129	72
Image-guided biopsy	137	77

400

401 **Table 2:** Type of disease-modifying IO procedures and number of trusts that offer each and
 402 percentage of total number of trusts (n=179).

403

Type of disease-modifying IO procedure	Number of trusts	Percentage (%)
Prostate ablation	2	1
Selective Internal Radiation Therapy (SIRT)	17	9
Bone ablation	18	10
Lung ablation	28	16
Liver ablation	39	22
Kidney ablation	39	22
Trans-arterial chemoembolization (TACE)	40	22

404

405

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: UK Map showing the overall provision of interventional oncology (IO) services throughout the UK.

199x254mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: UK Map showing what types of IO procedures (supportive and/ or disease modifying procedures) are undertaken in each NHS trust/ health board.

187x247mm (72 x 72 DPI)




Figure 3: Bar charts showing number of trusts offering: (A) Each type of supportive/symptomatic IO procedure and (B) Each type of disease-modifying IO procedure.

156x189mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 4: UK Map showing the provision of ablation services: (A) Renal ablation (B) Liver ablation (C) Bone ablation and (D) Lung ablation.

232x299mm (96 x 96 DPI)




Figure 5: UK Map showing the provision of (A) Trans-arterial chemoembolization (TACE) and (B) Selective internal radiation therapy (SIRT).

259x176mm (150 x 150 DPI)

ew only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Provision of Interventional Oncology Services in the United Kingdom: Pilot Study

SRQR Qualitative Research Checklist Adapted from:
OBrien BC; Harris IB; Beckman TJ; Reed DA; Cook DA. Standards for reporting
qualitative research: a synthesis of recommendations. Academic Medicine.
89(9):1245-51, 2014 Sep. DOI: 10.1097/ACM.0000000000000388

Number	Topic	Page number in manuscript
	Title and abstract	
S1	Title	1
S2	Abstract	3
	Introduction	
S3	Problem formation	5
S4	Purpose or research question	5
	Methods	
S5	Qualitative approach and research paradigm	6
S6	Researcher characteristics and reflexivity	6
S7	Context	5
S8	Sampling strategy	6
S9	Ethical issues pertaining to human subjects	n/a
S10	Data collection methods	6
S11	Data collection instruments and technologies	6
S12	Units of study	6
S13	Data processing	6
S14	Data analysis	6
S15	Techniques to enhance trustworthiness	6
	Results/ findings	
S16	Synthesis and interpretation	7-8
S17	Links to empirical data	7
	Discussion	
S18	Integration with prior work, implications, transferability, and contribution(s) to the field	8-10
S19	Limitations	11
	Other	
S20	Conflicts of Interest	12
S21	Funding	12

BMJ Open

Cross-sectional Study of the Provision of Interventional Oncology Services in the United Kingdom

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016631.R1
Article Type:	Research
Date Submitted by the Author:	03-Jul-2017
Complete List of Authors:	Zhong, Jim; St. James's University Hospital, Clinical and Interventional Radiology Atiiga, Peter; St. James's University Hospital, Clinical and Interventional Radiology Alcorn, Des; Gartnavel General Hospital, Interventional Radiology Kay, David; Gartnavel Hospital , Interventional Radiology Illing, Rowland; University College London Hospitals NHS Foundation Trust, Interventional Radiology Breen, David; University Hospital Southampton, Radiology Railton, Nicholas; Mid Essex Hospital Services NHS Trust, Interventional Radiology McCafferty, Ian; The Queen Elizabeth Hospital Birmingham, Interventional Radiology Haslem, Philip; Freeman Hospital, Interventional Radiology Wah, Tze; St. James's University Hospital, Clinical and Interventional Radiology
Primary Subject Heading:	Radiology and imaging
Secondary Subject Heading:	Oncology, Diagnostics, Medical education and training
Keywords:	Interventional radiology < RADIOLOGY & IMAGING, Adult oncology < ONCOLOGY, Cancer pain < ONCOLOGY, Gastrointestinal tumours < ONCOLOGY, Hepatobiliary tumours < ONCOLOGY, Kidney tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1 **1 Cross-sectional Study of the Provision of Interventional Oncology Services in the United**
2 **2 Kingdom**
3
4

5
6
7
8 Author List (in order):
9

- 10 1. Dr Jim Zhong (JZ), Radiology Registrar, Department of Clinical and Interventional Radiology,
11 Institute of Oncology, St James University Hospital, Leeds, LS9 7TF, United Kingdom.
12
13 2. Dr Peter Atiiga (P A), Foundation Year 2 Doctor, Department of Clinical and Interventional
14 Radiology, Institute of Oncology, St James University Hospital, Leeds, LS9 7TF, United
15 Kingdom.
16
17 3. *Dr Des J Alcorn (DJA), Consultant Radiologist, Gartnavel Hospital Glasgow G12 0YN, United
18 Kingdom
19
20 4. *Dr David Kay (DK), Consultant Interventional Radiologist, Gartnavel Hospital Glasgow G12 0
21 YN , United Kingdom
22
23 5. *Dr Rowland Illing (RI), Consultant Interventional Radiologist, University College Hospital,
24 Interventional Radiology, London, NW1 2BU, United Kingdom
25
26 6. *Dr David Breen (DB), Consultant Interventional Radiologist, Southampton University
27 Hospitals, Radiology, Southampton, United Kingdom
28
29 7. *Dr Nicholas Railton (N R), Consultant Interventional Radiologist, Mid Essex Hospital NHS
30 trust, Interventional Radiology, Chelmsford, United Kingdom
31
32 8. *Dr Ian J McCafferty (IJM), Consultant Interventional Radiologist, The Queen Elizabeth
33 Hospital Birmingham, University Hospital Birmingham NHS Trust, Dept. of Radiology,
34 Birmingham, B15 2TH, United Kingdom.
35
36 9. *Dr Philip J Haslam (PJH), Consultant Interventional Radiologist, Freeman Hospital,
37 Interventional Radiology, Newcastle-upon-Tyne, NE7 7DN, United Kingdom
38
39 10. *Dr Tze Min Wah (TMW), Professor of Radiology and Consultant Interventional Radiologist at
40 Leeds Teaching Hospitals Trust, IOUK Chair (British Society of Interventional Radiology),
41 Department of Clinical and Interventional Radiology, Institute of Oncology, St James University
42 Hospital, Leeds, LS9 7TF, United Kingdom.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 29 *All members of the Interventional Oncology United Kingdom (IOUK) group, a specialist interest
3
4 30 group of the British Society of Interventional Radiology (BSIR).
5
6 31

7
8 32 **Corresponding author:**

9
10 33 Professor Tze Min Wah

11
12 34 Department of Clinical and Interventional Radiology

13
14 35 Institute of Oncology

15
16 36 St James University Hospital

17
18 37 Leeds, LS9 7TF, United Kingdom.

19
20 38 E-mail address: tze.wah@nhs.net

21
22 39 Mobile: 07768010454
23
24 40

25
26 41 **Keywords:**

27
28 42 Interventional oncology

29
30 43 Radiology

31
32 44 Ablation

33
34 45 Networks
35
36 46

37
38 47 **Word Count (Excluding title page and abstract):**

39
40 48 2704
41
42 49

43
44 50 **Contributorship Statement**

45
46 51 Dr Jim Zhong (JZ) was also involved with designing the initial study concept, initial literature
47 52 search, designing the survey and questionnaire layout, all data collection and analysis, writing up
48 53 the manuscript and revising the manuscript in discussion with other authors. He has prepared the
49 54 manuscript for publication.

50
51 55 Dr Peter Atiiga (P A) was also involved with designing the survey and questionnaire layout, the
52 56 data collection and revising the manuscript in discussion with other authors.
53
54
55
56
57
58
59
60

1
2 57 Dr Des J Alcorn (DJA) was also involved with finalizing the initial study concept, reviewing and
3
4 58 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
5
6 59 manuscript for publication in discussion with the other authors.

7
8 60 Dr David Kay (DK) was also involved with finalizing the initial study concept, reviewing and
9
10 61 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
11
12 62 manuscript for publication in discussion with the other authors.

13
14 63 Dr Rowland Illing (RI) was also involved with finalizing the initial study concept, reviewing and
15
16 64 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
17
18 65 manuscript for publication in discussion with the other authors.

19
20 66 Dr David Breen (DB) was also involved with finalizing the initial study concept, reviewing and
21
22 67 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
23
24 68 manuscript for publication in discussion with the other authors.

25
26 69 Dr Nicholas Railton (N R) was also involved with finalizing the initial study concept, reviewing and
27
28 70 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
29
30 71 manuscript for publication in discussion with the other authors.

31
32 72 Dr Ian J McCafferty (IJM) was also involved with finalizing the initial study concept, reviewing and
33
34 73 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
35
36 74 manuscript for publication in discussion with the other authors.

37
38 75 Dr Philip J Haslam (PJH) was also involved with finalizing the initial study concept, reviewing and
39
40 76 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
41
42 77 manuscript for publication in discussion with the other authors.

43
44 78 Dr Tze Min Wah (TMW) was also involved with designing the initial study concept, approving the
45
46 79 survey and questionnaire layout, reviewing the results and analysis, and revising the manuscript in
47
48 80 discussion with other authors and approving the manuscript for publication in discussion with the
49
50 81 other authors.

51
52 82

53
54
55 83 Funding Statement: We thank AngioDynamics for funding the open access publication fee of this
56
57 84 study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

85 **Abstract**

86 **Objective:**

87 To map out the current provision of interventional oncology (IO) services in the United Kingdom.

88

89 **Design:**

90 Cross-sectional multi-centre study.

91

92 **Setting:**

93 All National Health Service (NHS) Trusts in England and Scottish, Welsh and Northern Ireland
94 health boards.

95

96 **Participants:**

97 Interventional Radiology departments in all NHS trusts/ health boards in the United Kingdom.

98

99 **Results**

100 A total of 179 NHS trusts/health boards were contacted. We received a 100% response rate. Only
101 19 (11%) institutions had an interventional oncology lead. 144 trusts (80%) provided IO services or
102 had a formal pathway of referral in place for patients to a recipient trust. 21 trusts (12%) had plans
103 to provide an IO service or formal referral pathway in the next 12 months only. 14 trusts (8%) did
104 not have a pathway of referral and no plans to implement one.

105 70 trusts (39%) offered supportive and disease-modifying procedures. 1 trust had a formal referral
106 pathway for supportive procedures. 73 trusts (41%) provided only supportive procedures
107 (diagnostic or therapeutic). Of these, 43 (59%) had a referral pathway for disease-modifying IO
108 procedures, either from a regional cancer network or through interventional radiology networks and
109 30 trusts (41%) did not have a referral pathway for disease-modifying procedures.

110

111 **Conclusion**

1
2 112 The provision of IO services in the UK is promising however collaborative networks are necessary
3
4 113 to ensure disease-modifying IO procedures are made accessible to all patients and to facilitate
5
6 114 larger registry data for research with commissioning of new services.
7

8 115

9 116 **Article Summary**

10 117 **Strengths and limitations of this study**

- 11 118 • 100% response rate from 179 Acute NHS Trusts and Health Boards throughout the United
12 119 Kingdom
- 13 120 • Provides comprehensive map of Interventional Oncology (IO) Services throughout the UK to
14 121 allow for more integrated cancer pathways on a national level.
- 15 122 • Map of the provision and geographic variation in disease modifying procedures such as tumour
16 123 ablation, which will allow for future planning of new IO services.
- 17 124 • Identifies types of supportive IO treatments, which are less routinely available apart from in
18 125 larger tertiary centres and therefore highlights areas to target for IO training.
- 19 126 • Limitations include those inherent to survey/ questionnaire format, such as subjective bias.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

131 Introduction

132 More than 1-in-3 people will develop cancer in their lifetime[1]. Since the NHS Cancer Plan in
133 2000, the Department of Health has strived to improve diagnosis and treatment[1]. As part of the
134 NHS Cancer Plan to deliver world-class cancer services, there is a drive to achieve better
135 outcomes by ensuring all patients have access to the best treatments available[2]. Wide variation
136 remains in performance across the country with major differences in access to cancer services[1].

137

138 Interventional oncology (IO), the use of image guided techniques to diagnose and treat cancer
139 patients is fast becoming the fourth pillar of oncological care alongside medical, surgical and
140 radiation oncology; The Royal College of Radiologists have set out best practice guidance for the
141 incorporation of interventional oncology into all cancer services nationally[3].

142 Supportive and symptomatic procedures were defined as those providing relief from tumour-
143 related symptoms but not modifying the underlying malignant disease process and include
144 diagnostic tests such as image guided biopsy which 'support' the provision of definitive
145 treatment[3]. These may be palliative procedures such as image guided drainage or stent
146 insertion. Disease modifying procedures were defined as those where the intent is to modify
147 malignant progression and/or modify the prognosis and include image-guided ablation, trans-
148 arterial chemoembolisation (TACE) and selective internal radiation therapy (SIRT).

149

150 There remains a significant shortage of interventional radiologists, who are the primary contributors
151 towards IO, with almost half of services in England unable to provide a local or networked out of
152 hours access to Interventional Radiology (IR)[4]. Undoubtedly this shortfall will have consequences
153 on the provision of elective IO services in the UK and potentially affect patient care through
154 limitations to access.

155

156 The current provision of Interventional Oncology services throughout the UK is unknown, therefore
157 NHS commissioners are unable to realistically factor IO into national cancer pathways as evident
158 in a previous Department of Health publication[1] which did not acknowledge IO as a treatment
159 option for patients.

1
2 160
3
4 161 The primary objective of this cross sectional study was to map out the current provision of
5
6 162 interventional oncology services in the UK. We also sought to uncover formal patient referral
7
8 163 pathways, the types of IO procedures offered and any limitations to providing IO. Ultimately, we
9
10 164 aim to develop IO networks and improve access to these treatments for cancer patients.

11 165
12
13 166 The survey was designed and undertaken in collaboration with the Interventional Oncology United
14
15 167 Kingdom (IOUK) group, a specialist interest group of the British Society of Interventional Radiology
16
17 168 (BSIR).

18
19
20 169

21 170 **Method**

22
23
24 171 No research ethics committee approval was required for this data-gathering project. No patient
25
26 172 identifiable data was captured.

27
28 173

29
30 174 This cross-sectional study involved all acute NHS Foundation Trusts in England[5] and all health
31
32 175 boards in Scotland, Wales and Northern Ireland which were contacted by email with the survey
33
34 176 (see supplementary material). This was followed by a telephone follow-up of all hospital radiology
35
36 177 departments that did not complete the survey within 2 weeks of the first email being sent out.
37
38 178 Telephone follow-up was conducted by a single radiologist (JZ). The survey could be completed by
39
40 179 any of the following: The head of department of radiology/ interventional radiology, any consultant
41
42 180 radiologist (diagnostic or interventional) or superintendent radiographer who has insight into the
43
44 181 local provision of services.

45
46 182

47
48 183 The surveys key points were:

- 49
50 184
- 51 185 • Are IO procedures offered in the trust?
 - 52 186 • If so, are these supportive treatments only or both supportive and disease-modifying?
 - 53 187 • We asked about the types of procedures undertaken
 - 54 188 • If no IO procedures are offered, is there an agreed formal pathway to another recipient trust?
- 55
56
57
58
59
60

- 1
2 189 • If there was no agreed pathway, was there a plan to provide IO or a pathway in the next 12
3
4 190 months?
5
6 191 • What barriers are there to setting up an IO service?
7

8 192

9
10 193 The full survey can be found in the online supplementary file.
11

12 194

13
14 195 Following the initial survey we followed up all trusts/ health boards which only offered supportive
15
16 196 treatments to see if there were formal referral pathways for disease-modifying procedures.
17

18 197 A formal referral pathway was defined as an existing mechanism of referral through a multi-
19
20 198 disciplinary team responsible for the patient, usually through a pre-existing local oncology or
21
22 199 radiology network.
23

24 200

25 26 201 **Results**

27
28 202 A total of 179 NHS trusts or health boards were contacted throughout the United Kingdom. We
29
30 203 received 100% response rate. The responses came from consultant interventional and diagnostic
31
32 204 radiologists and superintendent radiographers who had insight into the local provision of services.
33

34 205 143 trusts (80%) had an IR department in their trust. All trusts with an IR department offered IO
35
36 206 procedures. Only 19 (11%) institutions had an interventional oncology lead.

37
38 207 144 trusts (80%) provided IO services or had a formal pathway of referral in place for patients to a
39
40 208 recipient trust (Figure 1 and 2), of which 137 trusts (77%) stated what types of IO services they
41
42 209 offered. 21 trusts (12%) had plans to provide an IO service or formal referral pathway in the next
43
44 210 12 months only. 14 trusts (8%) did not have a pathway of referral and no plans to implement one.

45
46 211 70 trusts (39%) offered both supportive and disease-modifying procedures (Figure 3). 1 trust had a
47
48 212 formal referral pathway for supportive procedures. 73 trusts (41%) provided only supportive
49
50 213 procedures (diagnostic or therapeutic).
51

52 214

53
54 215 The number of trusts providing each supportive/ symptomatic IO procedure and disease-modifying
55
56 216 procedure are shown in table 1 and table 2. The 7 trusts that gave no details to which IO
57
58 217 procedures were offered were excluded when calculating the percentages
59
60

1 218 129 trusts out of 179 (72%) offered therapeutic IO procedures after excluding trusts, which only
2
3
4 219 offered diagnostic image guided biopsy. Figure 4 and 5 show the maps of the trusts providing each
5
6 220 type of disease-modifying procedure.
7

8 221

9
10 222 For England only, a total of 153 NHS Foundation trusts in England were contacted. 127 (83%)
11
12 223 trusts provided IO services or had a formal pathway of referral to another agreed recipient trust for
13
14 224 IO procedures (Figure 1). Out of the 26 that did not have a formal referral pathway, 21 (14%) trusts
15
16 225 had plans to provide an IO service or formal referral pathway for patients to have IO at another
17
18 226 trust within the next 12 months. 5 (3%) trusts did not have a pathway and had no plans of providing
19
20 227 IO or a referral pathway in the next 12 months (Figure 1). 57 out of 127 (45%) trusts providing IO
21
22 228 offered both supportive and disease modifying procedures (Figure 3). 70 out of 127 (55%)
23
24 229 provided only supportive procedures.
25

26 230

27
28 231 For Scotland, 10 out of 14 health boards provided IO or had a formal pathway of referral to a
29
30 232 specialist hospital in another health board (Glasgow or Edinburgh). Of these, 8 health boards
31
32 233 provided both supportive and disease-modifying IO whilst 2 provided only supportive IO. 4 health
33
34 234 boards (29%) did not provide IO and did not have plans to provide a pathway in the next 12
35
36 235 months.
37

38 236

39
40 237 For Wales, 6 out of 7 health boards (86%) provided IO or had a referral pathway in place. 4 Welsh
41
42 238 health boards (57%) provided both types of IO, one health board provided only supportive IO and
43
44 239 one had a formal referral pathway. One Welsh health board did not offer IO or have a referral
45
46 240 pathway implemented in the next 12 months.
47

48 241 Only 1 out of 5 health boards in Northern Ireland (Belfast Health and Social Care Trust) provided
49
50 242 IO (both types). 4 health boards did not have plans to offer IO or have a referral pathway
51
52 243 implemented in the next 12 months.
53

54 244

55
56 245 Out of the 70 English NHS trusts and 3 Scottish/ Welsh Health Boards, which provided only
57
58 246 supportive IO, 43 trusts (59%) had a referral pathway to another hospital/ trust for disease-

1
2 247 modifying IO procedures. This was from a local regional cancer network referral initiated following
3
4 248 a formal discussion at the multi-disciplinary team meeting or through interventional radiology
5
6 249 networks. 30 trusts (41%) did not have a referral pathway for disease-modifying procedures.
7

8 250

9
10 251 The most common barriers to providing disease-modifying IO were insufficient funding, lack of
11
12 252 staff, lack of support from other non-radiology clinicians, having a pathway already in place and
13
14 253 problems with recruitment into IR.

15 254

16 255 **Discussion**

17
18
19
20 256 Overall, the provision of IO in the UK is unevenly spread.. Based on the Royal College of
21
22 257 Radiologists definition of 'supportive' IO[1], this encompasses many routine procedures that can be
23
24 258 carried out by diagnostic radiologists which is reflected in the excellent availability of these
25
26 259 procedures throughout the UK. Beyond basic image-guided drainage procedures, the provision of
27
28 260 specialist vascular, gastro-intestinal or biliary 'symptomatic' intervention is less routinely available
29
30 261 apart from in the larger tertiary centers which were also providing disease-modifying IO. This
31
32 262 highlights important areas to target nationally for radiology and IO training.
33

34 263

35
36 264 Given the vital role of IR in the management of critically ill patients, the comprehensive provision of
37
38 265 supportive IO in most parts of the UK reflects the drive to train more radiologists with basic
39
40 266 interventional skills, which are also transferrable to IO[6]. Only 1 trust without an IR department
41
42 267 offered IO. We were unable to capture if most of the IO procedures were done by the IR
43
44 268 department or not, with institutions occasionally splitting non-vascular (e.g. ablation) and vascular
45
46 269 interventions (e.g. transarterial chemoembolization - TACE) between the diagnostic radiologists
47
48 270 and the interventional radiologists who also have to cover the on-call service for non-oncology
49
50 271 related emergency procedures such as trauma, bleeding or aortic syndromes. A major recruitment
51
52 272 drive currently is the provision of on-call IR services and given the overlap between IO and IR
53
54 273 training, emergency IR provision is therefore linked with the provision of IO services not only for
55
56 274 maintaining the availability of supportive services in small district hospitals but also for the
57
58 275 provision of disease-modifying IO in specialist centres. Additional need for interventional
59
60

1
2 276 radiographers and nursing cover for IO services should not be overlooked either to allow a new IO
3
4 277 service to be introduced.
5
6 278
7
8 279 We acknowledge that disease-modifying treatments form a smaller proportion of IO workload and
9
10 280 centralization of this is happening as part of the current NHS model for cancer services[7]. One
11
12 281 argument for this model in the context of IO is to ensure that more complex IO procedures are
13
14 282 undertaken by those who carry out a sufficient number of cases to maintain competency however
15
16 283 this should not preclude suitable patients from being referred due to their geographic location.
17
18 284 There are NHS trusts/ boards, most noticeably in rural Scotland and Northern Ireland where
19
20 285 access to disease-modifying IO services appears limited and linking up with neighboring hospitals
21
22 286 to set up formal referral pathways should be considered. What also remains unclear is what the
23
24 287 current demand for IO services are generally but particularly in these rural regions, as we have no
25
26 288 data to suggest current arrangements are sub-optimal. It would not be necessary or appropriate for
27
28 289 all providers to liaise with IO services, and these should be facilitated through regional cancer
29
30 290 networks with more integrated pathways of care[7]. Currently there appears to be 136 out of 153
31
32 291 acute NHS trusts in England, which are listed to offer acute oncology services[8]. Further work is
33
34 292 required to elucidate whether there is any discrepancy in the regional demand and supply of
35
36 293 disease-modifying IO.
37
38 294
39
40 295 The perceived barriers to starting up elective disease-modifying services stemmed from shortfalls
41
42 296 in funding, staffing and support from other specialties. With tertiary centres undertaking much
43
44 297 higher volumes of disease modifying IO procedures, some smaller district general hospitals felt
45
46 298 unsupported in starting up their own service, from financial considerations when purchasing the
47
48 299 equipment to garnering support from allied specialties such as surgery and oncology. This is an
49
50 300 important point as it highlights the need for greater awareness of the role of the interventional
51
52 301 radiologist in oncology care and we must strive to work even closer with oncologists given the new
53
54 302 evidence suggesting the added value of combination therapies and incorporation of IO procedures
55
56 303 into European cancer guidelines[9]. However, with the current model of centralizing cancer
57
58 304 services, these barriers would only be an issue if cancer centers were unable to provide IO. To
59
60

1
2 305 improve patient selection for complex IO procedures, interventional radiologists should have a
3
4 306 regular role in multi-disciplinary team meetings. With only 19 institutions (11%) currently having a
5
6 307 formal IO lead clinician, there is a role for dispersed leadership to achieve structural change in
7
8 308 established cancer networks.

9
10 309
11 310 Local expertise and facilities help determine the IO that is offered. An example is the provision of
12
13 311 disease-modifying IO for the liver, which is centred around the national liver transplant units[10].
14
15 312 Clearly image-guided tumour ablation, TACE and SIRT are effective therapies than can be used
16
17 313 solely or in combination with chemotherapy or surgery to improve the outcome of such patients.
18
19 314 [11 12]. Participation in MDT discussions will also allow interventional radiologists and radiologists
20
21 315 familiar with IO Techniques to educate other clinicians on the role of IO in the management of
22
23 316 patients and contribute towards improvement and restructuring of services. This will also open
24
25 317 opportunities to undertake collaborative research that will be higher impact and wider reaching to
26
27 318 the oncology community.

28
29 319
30
31 320 The recurrent issue of lack of staffing within IR remains a barrier. Despite the promising provision
32
33 321 of supportive IO, most departments are struggling to cope with the demand for basic vascular,
34
35 322 urological and biliary procedures, necessary to provide a sustainable out of hours service, without
36
37 323 compounding this with additional workload and need for additional training for disease-modifying
38
39 324 IO.

40
41 325
42
43 326 Changes to the delivery of healthcare throughout the UK demands that IO treatments can
44
45 327 demonstrate not only a therapeutic benefit but also cost-effectiveness. For units with a referral
46
47 328 pathway for disease-modifying IO, there was a common theme that this set-up was more cost
48
49 329 effective than starting a service from scratch. Without knowledge of the actual demand for these IO
50
51 330 procedures, there is no answer to this currently, and clinical investigators must incorporate
52
53 331 measures of cost-effectiveness and patient-reported outcomes into large-scale studies to provide
54
55 332 more robust evidence[13]. Even if these IO treatments can be shown to be equally effective
56
57 333 compared with the current standard of care but with significantly less morbidity, then it will allow
58
59
60

1
2 334 the specialty to develop further, however current studies have not offered definitive
3
4 335 conclusions[14]. Building upon the knowledge of these IO networks will allow better registry data
5
6 336 that can be used to derive larger cohorts for future trials and also commissioning of new services.
7

8 337

9
10 338 The limitations of the present study include those inherent in the survey/ questionnaire format such
11
12 339 as the subjective element depending on whether a superintendent radiographer or consultant
13
14 340 radiologist responded given their underlying experience and knowledge of their radiology services
15
16 341 which could impact on the detail of their survey answers. The strengths of the survey include 100%
17
18 342 response rate from 179 acute NHS trusts/ health boards which allowed a comprehensive map of
19
20 343 both supportive and disease-modifying IO procedures offered in the UK that will help direct
21
22 344 radiology/IO training, future planning of new IO services and allow for more integrated cancer
23
24 345 pathways.
25

26 346

27 347 **Conclusion**

28
29
30 348 The provision of IO services in the UK is promising however collaboration and networking is
31
32 349 necessary to ensure disease-modifying IO procedures are made accessible to all patients
33
34 350 throughout the UK and to facilitate improved registry data collection for research and
35
36 351 commissioning or funding of new services.
37

38 352

39
40 353
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 354

2 355

3
4
5 356 All authors have completed the ICMJE uniform disclosure form at
6
7 357 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted
8
9 358 work; no financial relationships with any organisations that might have an interest in the submitted
10
11 359 work in the previous three years; no other relationships or activities that could appear to have
12
13 360 influenced the submitted work

14 361

15
16 362 Transparency declaration: I affirm that the manuscript is an honest, accurate, and transparent
17
18 363 account of the study being reported; that no important aspects of the study have been omitted; and
19
20 364 that any discrepancies from the study as planned (and, if relevant, registered) have been
21
22 365 explained.

23 366

24 367 Data sharing: no additional data available.

25 368

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

369 **References**

- 370 1. NHS England Department of Health and Public Health England. Progress in improving
371 cancer services and outcomes in England. 2015.
- 372 2. NHS England. Achieving World-Class Cancer Outcomes: Taking the strategy forward. 2016
- 373 3. Royal College of Radiologists. Interventional oncology: guidance for service delivery. 2013.
374 http://www.rcr.ac.uk/sites/default/files/publication/RCR%2813%29_IO_0.pdf.
375 (accessed 6th June 2016)
- 376 4. Centre for Workforce Intelligence. Securing the future workforce supply: clinical radiology
377 stocktake. In: London: Centre for Workforce Intelligence. 2012.
- 378 5. UK Government. Transparency data NHS foundation trust directory. 2015.
379 [https://http://www.gov.uk/government/publications/nhs-foundation-trust-](https://http://www.gov.uk/government/publications/nhs-foundation-trust-directory/nhs-foundation-trust-directory)
380 [directory/nhs-foundation-trust-directory](https://http://www.gov.uk/government/publications/nhs-foundation-trust-directory/nhs-foundation-trust-directory). (accessed 6th June 2016)
- 381 6. Royal College of Radiologists. Provision of Interventional Radiology Services. 2013.
382 [https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR\(](https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR(14)12_POIR.pdf)
383 [14\)12_POIR.pdf](https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR(14)12_POIR.pdf). (accessed 6th June 2016)
- 384 7. Independent Cancer Taskforce Cancer Research UK. Achieving World-Class Cancer
385 Outcomes, A strategy for England 2015-2020. 2015
- 386 8. National Peer Review Programme. My Cancer Treatment. 2016.
387 <http://www.mycancertreatment.nhs.uk/find-your-treatment/>. (accessed 6th June
388 2016)
- 389 9. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice
390 Guidelines for diagnosis, treatment and follow-up. *Annals of oncology : official journal*
391 *of the European Society for Medical Oncology / ESMO* 2016;**27**(suppl 5):v58-v68 doi:
392 10.1093/annonc/mdw328[published Online First: Epub Date]].

- 1
2 393 10. NHS Blood and Transplant. Transplant Units in the UK. Secondary Transplant Units in the
3
4 394 UK. 2016. <http://www.odt.nhs.uk/transplantation/transplant-units-in-uk/>. (accessed
5
6 395 6th June 2016)
7
8
9 396 11. Hickey R, Vouche M, Sze DY, et al. Cancer Concepts and Principles: Primer for the
10
11 397 Interventional Oncologist-Part I. Journal of Vascular and Interventional Radiology
12
13 398 2013;**24**(8):1157-64 doi: 10.1016/j.jvir.2013.04.024[published Online First: Epub
14
15 399 Date]].
16
17
18 400 12. Hickey R, Vouche M, Sze DY, et al. Cancer Concepts and Principles: Primer for the
19
20 401 Interventional Oncologist-Part II. Journal of Vascular and Interventional Radiology
21
22 402 2013;**24**(8):1167-88 doi: 10.1016/j.jvir.2013.04.023[published Online First: Epub
23
24 403 Date]].
25
26
27 404 13. Franklin JM, GebSKI V, Poston GJ, et al. Clinical trials of interventional oncology-moving
28
29 405 from efficacy to outcomes. Nature reviews. Clinical oncology 2015;**12**(2):93-104 doi:
30
31 406 10.1038/nrclinonc.2014.199[published Online First: Epub Date]].
32
33
34 407 14. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014
35
36 408 update. European urology 2015;**67**(5):913-24 doi:
37
38 409 10.1016/j.eururo.2015.01.005[published Online First: Epub Date]].
39
40 410
41 411
42
43 412
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 413 **Figure Legends:**

3
4 414 **Figure 1:** UK Map showing the overall provision of interventional oncology (IO) services
5
6 415 throughout the UK.

7
8 416 **Figure 2:** Middle pie chart (A) displaying total number/percentage of trusts which offer IO or have a
9
10 417 referral pathway, number which plan to set up IO service or referral pathway in the next 12 months
11
12 418 (All English trusts) and those without any plans to set up a IO service pathway. The top (B) and
13
14 419 bottom (C) pie charts display the breakdown of healthcare trusts/ health boards by country.

15
16 420 **Figure 3:** UK Map showing what types of IO procedures (supportive and/ or disease modifying
17
18 421 procedures) are undertaken in each NHS trust/ health board.

19
20 422 **Figure 4:** UK Map showing the provision of ablation services: (A) Renal ablation (B) Liver ablation
21
22 423 (C) Bone ablation and (D) Lung ablation.

23
24 424 **Figure 5:** UK Map showing the provision of (A) Trans-arterial chemoembolization (TACE) and (B)
25
26 425 Selective internal radiation therapy (SIRT).

27
28 426

29
30 427

31
32 428

33
34 429

35
36 430

37
38

39
40

41
42

43
44

45
46

47
48

49
50

51
52

53
54

55
56

57
58

59
60

431 **Table Legends**

432 **Table 1:** Type of supportive/ symptomatic IO procedure and number of trusts that offer each and
 433 percentage of total number of trusts that provided information on the types of procedure offered
 434 (n=137). 7 out of 144 who offered IO did not include what procedures were offered and were
 435 excluded from calculations.

Type of supportive/ symptomatic IO procedure	Number of trusts	Percentage of total (%)
Image-guided biopsy	137	100
Nephrostomy	129	94
Image-guided drainage	128	93
Central venous catheter	125	91
Ureteric stenting	124	91
Biliary drainage and stenting	118	86
Vena caval filtration	88	64
Gastrointestinal stenting	87	64
Percutaneous Trans-hepatic Cholangiography (PTC)	84	61
Enteral tube placement e.g. Radiologically Inserted Gastrostomy (RIG)	81	59
Vena caval stenting	79	58
Ascitic diversion	39	28
Vertebroplasty	6	4
Isolated perfusion chemotherapy	5	4

436

437 **Table 2:** Type of disease-modifying IO procedures and number of trusts that offer each and
 438 percentage of total number of trusts (n=179).

Type of disease-modifying IO procedure	Number of trusts	Percentage (%)
Trans-arterial chemoembolization (TACE)	40	22
Liver ablation	39	22
Kidney ablation	39	22
Lung ablation	28	16
Bone ablation	18	10
Selective Internal Radiation Therapy (SIRT)	17	9
Prostate ablation	2	1

439

440


441

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1: UK Map showing the overall provision of interventional oncology (IO) services throughout the UK.

94x127mm (300 x 300 DPI)



Middle pie chart (A) displaying total number/percentage of trusts which offer IO or have a referral pathway, number which plan to set up IO service or referral pathway in the next 12 months (All English trusts) and those without any plans to set up a IO service pathway. The top (B) and bottom (C) pie charts display the breakdown of healthcare trusts/ health boards by country.

196x190mm (72 x 72 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: UK Map showing what types of IO procedures (supportive and/ or disease modifying procedures) are undertaken in each NHS trust/ health board.

118x157mm (300 x 300 DPI)



Figure 4: UK Map showing the provision of ablation services: (A) Renal ablation (B) Liver ablation (C) Bone ablation and (D) Lung ablation.

232x299mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 5: UK Map showing the provision of (A) Trans-arterial chemoembolization (TACE) and (B) Selective internal radiation therapy (SIRT).

259x176mm (150 x 150 DPI)

ew only

Cross-sectional Study of the Provision of Interventional Oncology Services in the United Kingdom

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page in Manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	13
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8

		(b) Indicate number of participants with missing data for each variable of interest	n/a
Outcome data	15*	Report numbers of outcome events or summary measures	8-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	n/a
		(b) Report category boundaries when continuous variables were categorized	8-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-10
Discussion			
Key results	18	Summarise key results with reference to study objectives	10-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Cross-sectional Study of the Provision of Interventional Oncology Services in the United Kingdom

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016631.R2
Article Type:	Research
Date Submitted by the Author:	18-Jul-2017
Complete List of Authors:	Zhong, Jim; St. James's University Hospital, Clinical and Interventional Radiology Atiiga, Peter; St. James's University Hospital, Clinical and Interventional Radiology Alcorn, Des; Gartnavel General Hospital, Interventional Radiology Kay, David; Gartnavel Hospital , Interventional Radiology Illing, Rowland; University College London Hospitals NHS Foundation Trust, Interventional Radiology Breen, David; University Hospital Southampton, Radiology Railton, Nicholas; Mid Essex Hospital Services NHS Trust, Interventional Radiology McCafferty, Ian; The Queen Elizabeth Hospital Birmingham, Interventional Radiology Haslem, Philip; Freeman Hospital, Interventional Radiology Wah, Tze; St. James's University Hospital, Clinical and Interventional Radiology
Primary Subject Heading:	Radiology and imaging
Secondary Subject Heading:	Oncology, Diagnostics, Medical education and training
Keywords:	Interventional radiology < RADIOLOGY & IMAGING, Adult oncology < ONCOLOGY, Cancer pain < ONCOLOGY, Gastrointestinal tumours < ONCOLOGY, Hepatobiliary tumours < ONCOLOGY, Kidney tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1 **1 Cross-sectional Study of the Provision of Interventional Oncology Services in the United**
2 **2 Kingdom**
3
4

5
6
7
8 4 Author List (in order):
9

- 10 5 1. Dr Jim Zhong (JZ), Radiology Registrar, Department of Clinical and Interventional Radiology,
11 Institute of Oncology, St James University Hospital, Leeds, LS9 7TF, United Kingdom.
12
13 7 2. Dr Peter Atiiga (P A), Foundation Year 2 Doctor, Department of Clinical and Interventional
14 Radiology, Institute of Oncology, St James University Hospital, Leeds, LS9 7TF, United
15 Kingdom.
16
17 10 3. *Dr Des J Alcorn (DJA), Consultant Radiologist, Gartnavel Hospital Glasgow G12 0YN, United
18 Kingdom
19
20 12 4. *Dr David Kay (DK), Consultant Interventional Radiologist, Gartnavel Hospital Glasgow G12 0
21 YN , United Kingdom
22
23 14 5. *Dr Rowland Illing (RI), Consultant Interventional Radiologist, University College Hospital,
24 Interventional Radiology, London, NW1 2BU, United Kingdom
25
26 16 6. *Dr David Breen (DB), Consultant Interventional Radiologist, Southampton University
27 Hospitals, Radiology, Southampton, United Kingdom
28
29 18 7. *Dr Nicholas Railton (N R), Consultant Interventional Radiologist, Mid Essex Hospital NHS
30 trust, Interventional Radiology, Chelmsford, United Kingdom
31
32 20 8. *Dr Ian J McCafferty (IJM), Consultant Interventional Radiologist, The Queen Elizabeth
33 Hospital Birmingham, University Hospital Birmingham NHS Trust, Dept. of Radiology,
34 Birmingham, B15 2TH, United Kingdom.
35
36 23 9. *Dr Philip J Haslam (PJH), Consultant Interventional Radiologist, Freeman Hospital,
37 Interventional Radiology, Newcastle-upon-Tyne, NE7 7DN, United Kingdom
38
39 25 10. *Dr Tze Min Wah (TMW), Professor of Radiology and Consultant Interventional Radiologist at
40 Leeds Teaching Hospitals Trust, IOUK Chair (British Society of Interventional Radiology),
41 Department of Clinical and Interventional Radiology, Institute of Oncology, St James University
42 Hospital, Leeds, LS9 7TF, United Kingdom.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 29 *All members of the Interventional Oncology United Kingdom (IOUK) group, a specialist interest
3
4 30 group of the British Society of Interventional Radiology (BSIR).
5
6 31

7
8 32 **Corresponding author:**

9
10 33 Professor Tze Min Wah

11
12 34 Department of Clinical and Interventional Radiology

13
14 35 Institute of Oncology

15
16 36 St James University Hospital

17
18 37 Leeds, LS9 7TF, United Kingdom.

19
20 38 E-mail address: tze.wah@nhs.net

21
22 39 Mobile: 07768010454
23
24 40

25
26 41 **Keywords:**

27
28 42 Interventional oncology

29
30 43 Radiology

31
32 44 Ablation

33
34 45 Networks
35
36 46

37
38 47 **Word Count (Excluding title page and abstract):**

39
40 48 2704
41
42 49

43
44 50 **Contributorship Statement**

45
46 51 Dr Jim Zhong (JZ) was also involved with designing the initial study concept, initial literature
47 52 search, designing the survey and questionnaire layout, all data collection and analysis, writing up
48 53 the manuscript and revising the manuscript in discussion with other authors. He has prepared the
49 54 manuscript for publication.

50
51 55 Dr Peter Atiiga (P A) was also involved with designing the survey and questionnaire layout, the
52 56 data collection and revising the manuscript in discussion with other authors.
53
54
55
56
57
58
59
60

1
2 57 Dr Des J Alcorn (DJA) was also involved with finalizing the initial study concept, reviewing and
3
4 58 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
5
6 59 manuscript for publication in discussion with the other authors.

7
8 60 Dr David Kay (DK) was also involved with finalizing the initial study concept, reviewing and
9
10 61 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
11
12 62 manuscript for publication in discussion with the other authors.

13
14 63 Dr Rowland Illing (RI) was also involved with finalizing the initial study concept, reviewing and
15
16 64 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
17
18 65 manuscript for publication in discussion with the other authors.

19
20 66 Dr David Breen (DB) was also involved with finalizing the initial study concept, reviewing and
21
22 67 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
23
24 68 manuscript for publication in discussion with the other authors.

25
26 69 Dr Nicholas Railton (N R) was also involved with finalizing the initial study concept, reviewing and
27
28 70 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
29
30 71 manuscript for publication in discussion with the other authors.

31
32 72 Dr Ian J McCafferty (IJM) was also involved with finalizing the initial study concept, reviewing and
33
34 73 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
35
36 74 manuscript for publication in discussion with the other authors.

37
38 75 Dr Philip J Haslam (PJH) was also involved with finalizing the initial study concept, reviewing and
39
40 76 approving the survey and questionnaire layout, reviewing the data and analysis and approving the
41
42 77 manuscript for publication in discussion with the other authors.

43
44 78 Dr Tze Min Wah (TMW) was also involved with designing the initial study concept, approving the
45
46 79 survey and questionnaire layout, reviewing the results and analysis, and revising the manuscript in
47
48 80 discussion with other authors and approving the manuscript for publication in discussion with the
49
50 81 other authors.

51
52 82

53
54
55 83 Funding Statement: We thank AngioDynamics for funding the open access publication fee of this
56
57 84 study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

85 **Abstract**

86 **Objective:**

87 To map out the current provision of interventional oncology (IO) services in the United Kingdom.

88

89 **Design:**

90 Cross-sectional multi-centre study.

91

92 **Setting:**

93 All National Health Service (NHS) Trusts in England and Scottish, Welsh and Northern Ireland
94 health boards.

95

96 **Participants:**

97 Interventional Radiology departments in all NHS trusts/ health boards in the United Kingdom.

98

99 **Results**

100 A total of 179 NHS trusts/health boards were contacted. We received a 100% response rate. Only
101 19 (11%) institutions had an interventional oncology lead. 144 trusts (80%) provided IO services or
102 had a formal pathway of referral in place for patients to a recipient trust. 21 trusts (12%) had plans
103 to provide an IO service or formal referral pathway in the next 12 months only. 14 trusts (8%) did
104 not have a pathway of referral and no plans to implement one.

105 70 trusts (39%) offered supportive and disease-modifying procedures. 1 trust had a formal referral
106 pathway for supportive procedures. 73 trusts (41%) provided only supportive procedures
107 (diagnostic or therapeutic). Of these, 43 (59%) had a referral pathway for disease-modifying IO
108 procedures, either from a regional cancer network or through interventional radiology networks and
109 30 trusts (41%) did not have a referral pathway for disease-modifying procedures.

110

111 **Conclusion**

1
2 112 The provision of IO services in the UK is promising however collaborative networks are necessary
3
4 113 to ensure disease-modifying IO procedures are made accessible to all patients and to facilitate
5
6 114 larger registry data for research with commissioning of new services.
7

8 115

9
10 116 **Article Summary**

11
12 117 **Strengths and limitations of this study**

- 13
14 118 • This is the first study to investigate the provision of Interventional Oncology (IO) Services in the
15
16 119 UK.
17
18 120 • The sample size is large and covers all acute trusts and health boards in the UK.
19
20 121 • Cross-sectional study design allowed for multiple variables to be studied
21
22 122 • Data was self-reported therefore at risk of incompleteness.
23
24 123 • Limitations include those inherent to survey/ questionnaire format, including subjective bias.
25

26 124

27
28 125

29
30 126

31
32 127 **We have read and understood BMJ policy on declaration of interests and declare that we**

33
34 128 **have no competing interests**
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 129 **Introduction**

3
4 130 More than 1-in-3 people will develop cancer in their lifetime[1]. Since the NHS Cancer Plan in
5
6 131 2000, the Department of Health has strived to improve diagnosis and treatment[1]. As part of the
7
8 132 NHS Cancer Plan to deliver world-class cancer services, there is a drive to achieve better
9
10 133 outcomes by ensuring all patients have access to the best treatments available[2]. Wide variation
11
12 134 remains in performance across the country with major differences in access to cancer services[1].

13
14 135

15
16 136 Interventional oncology (IO) the use of image guided techniques to diagnose and treat cancer
17
18 137 patients is fast becoming the fourth pillar of oncological care alongside medical, surgical and
19
20 138 radiation oncology; The Royal College of Radiologists have set out best practice guidance for the
21
22 139 incorporation of interventional oncology into all cancer services nationally[3].

23
24 140 Supportive and symptomatic procedures were defined as those providing relief from tumour-
25
26 141 related symptoms but not modifying the underlying malignant disease process and include
27
28 142 diagnostic tests such as image guided biopsy which 'support' the provision of definitive
29
30 143 treatment[3]. These may be palliative procedures such as image guided drainage or stent
31
32 144 insertion. Disease modifying procedures were defined as those where the intent is to modify
33
34 145 malignant progression and/or modify the prognosis and include image-guided ablation, trans-
35
36 146 arterial chemoembolisation (TACE) and selective internal radiation therapy (SIRT).

37
38 147

39
40 148 There remains a significant shortage of interventional radiologists, who are the primary contributors
41
42 149 towards IO, with almost half of services in England unable to provide a local or networked out of
43
44 150 hours access to Interventional Radiology (IR)[4]. Undoubtedly this shortfall will have consequences
45
46 151 on the provision of elective IO services in the UK and potentially affect patient care through
47
48 152 limitations to access.

49
50 153

51
52 154 The current provision of Interventional Oncology services throughout the UK is unknown, therefore
53
54 155 NHS commissioners are unable to realistically factor IO into national cancer pathways as evident
55
56 156 in a previous Department of Health publication[1] which did not acknowledge IO as a treatment
57
58 157 option for patients.
59
60

1
2 158
3
4 159 The primary objective of this cross sectional study was to map out the current provision of
5
6 160 interventional oncology services in the UK. We also sought to uncover formal patient referral
7
8 161 pathways, the types of IO procedures offered and any limitations to providing IO. Ultimately, we
9
10 162 aim to develop IO networks and improve access to these treatments for cancer patients.

11 163
12
13
14 164 The survey was designed and undertaken in collaboration with the Interventional Oncology United
15
16 165 Kingdom (IOUK) group, a specialist interest group of the British Society of Interventional Radiology
17
18 166 (BSIR).

19
20 167

21 168 **Method**

22
23
24 169 No research ethics committee approval was required for this data-gathering project. No patient
25
26 170 identifiable data was captured.

27
28 171

29
30 172 This cross-sectional study involved all acute NHS Foundation Trusts in England[5] and all health
31
32 173 boards in Scotland, Wales and Northern Ireland which were contacted by email with the survey
33
34 174 (see supplementary material). This was followed by a telephone follow-up of all hospital radiology
35
36 175 departments that did not complete the survey within 2 weeks of the first email being sent out.
37
38 176 Telephone follow-up was conducted by a single radiologist (JZ). The survey could be completed by
39
40 177 any of the following: The head of department of radiology/ interventional radiology, any consultant
41
42 178 radiologist (diagnostic or interventional) or superintendent radiographer who has insight into the
43
44 179 local provision of services.

45
46 180

47
48 181 The surveys key points were:

- 49
50 182
- 51 183 • Are IO procedures offered in the trust?
 - 52 184 • If so, are these supportive treatments only or both supportive and disease-modifying?
 - 53 185 • We asked about the types of procedures undertaken
 - 54 186 • If no IO procedures are offered, is there an agreed formal pathway to another recipient trust?
- 55
56
57
58
59
60

- 1
2 187 • If there was no agreed pathway, was there a plan to provide IO or a pathway in the next 12
3
4 188 months?
5
6 189 • What barriers are there to setting up an IO service?
7

8 190

9
10 191 The full survey can be found in the online supplementary file.
11

12 192

13
14 193 Following the initial survey we followed up all trusts/ health boards which only offered supportive
15
16 194 treatments to see if there were formal referral pathways for disease-modifying procedures.
17

18 195 A formal referral pathway was defined as an existing mechanism of referral through a multi-
19
20 196 disciplinary team responsible for the patient, usually through a pre-existing local oncology or
21
22 197 radiology network.
23

24 198

25 199 **Results**

26
27
28 200 A total of 179 NHS trusts or health boards were contacted throughout the United Kingdom. We
29
30 201 received 100% response rate. The responses came from consultant interventional and diagnostic
31
32 202 radiologists and superintendent radiographers who had insight into the local provision of services.
33

34 203 143 trusts (80%) had an IR department in their trust. All trusts with an IR department offered IO
35
36 204 procedures. Only 19 (11%) institutions had an interventional oncology lead.

37
38 205 144 trusts (80%) provided IO services or had a formal pathway of referral in place for patients to a
39
40 206 recipient trust (Figure 1 and 2), of which 137 trusts (77%) stated what types of IO services they
41
42 207 offered. 21 trusts (12%) had plans to provide an IO service or formal referral pathway in the next
43
44 208 12 months only. 14 trusts (8%) did not have a pathway of referral and no plans to implement one.

45
46 209 70 trusts (39%) offered both supportive and disease-modifying procedures (Figure 3). 1 trust had a
47
48 210 formal referral pathway for supportive procedures. 73 trusts (41%) provided only supportive
49
50 211 procedures (diagnostic or therapeutic).
51

52 212

53
54
55 213 The number of trusts providing each supportive/ symptomatic IO procedure and disease-modifying
56
57 214 procedure are shown in table 1 and table 2. The 7 trusts that gave no details to which IO
58
59 215 procedures were offered were excluded when calculating the percentages
60

1 216 129 trusts out of 179 (72%) offered therapeutic IO procedures after excluding trusts, which only
2
3
4 217 offered diagnostic image guided biopsy. Figure 4 and 5 show the maps of the trusts providing each
5
6 218 type of disease-modifying procedure.
7

8 219

9
10 220 For England only, a total of 153 NHS Foundation trusts in England were contacted. 127 (83%)
11 221 trusts provided IO services or had a formal pathway of referral to another agreed recipient trust for
12 222 IO procedures (Figure 1). Out of the 26 that did not have a formal referral pathway, 21 (14%) trusts
13 223 had plans to provide an IO service or formal referral pathway for patients to have IO at another
14 224 trust within the next 12 months. 5 (3%) trusts did not have a pathway and had no plans of providing
15 225 IO or a referral pathway in the next 12 months (Figure 1). 57 out of 127 (45%) trusts providing IO
16 226 offered both supportive and disease modifying procedures (Figure 3). 70 out of 127 (55%)
17 227 provided only supportive procedures.
18
19
20
21
22
23
24
25

26 228

27
28 229 For Scotland, 10 out of 14 health boards provided IO or had a formal pathway of referral to a
29 230 specialist hospital in another health board (Glasgow or Edinburgh). Of these, 8 health boards
30 231 provided both supportive and disease-modifying IO whilst 2 provided only supportive IO. 4 health
31 232 boards (29%) did not provide IO and did not have plans to provide a pathway in the next 12
32 233 months.
33
34
35
36
37

38 234

39
40 235 For Wales, 6 out of 7 health boards (86%) provided IO or had a referral pathway in place. 4 Welsh
41 236 health boards (57%) provided both types of IO, one health board provided only supportive IO and
42 237 one had a formal referral pathway. One Welsh health board did not offer IO or have a referral
43 238 pathway implemented in the next 12 months.
44
45
46
47

48 239 Only 1 out of 5 health boards in Northern Ireland (Belfast Health and Social Care Trust) provided
49 240 IO (both types). 4 health boards did not have plans to offer IO or have a referral pathway
50 241 implemented in the next 12 months.
51
52
53
54

55 242

56 243 Out of the 70 English NHS trusts and 3 Scottish/ Welsh Health Boards, which provided only
57 244 supportive IO, 43 trusts (59%) had a referral pathway to another hospital/ trust for disease-
58
59
60

1
2 245 modifying IO procedures. This was from a local regional cancer network referral initiated following
3
4 246 a formal discussion at the multi-disciplinary team meeting or through interventional radiology
5
6 247 networks. 30 trusts (41%) did not have a referral pathway for disease-modifying procedures.
7

8 248

9
10 249 The most common barriers to providing disease-modifying IO were insufficient funding, lack of
11
12 250 staff, lack of support from other non-radiology clinicians, having a pathway already in place and
13
14 251 problems with recruitment into IR.

15 252

18 253 **Discussion**

19
20 254 Overall, the provision of IO in the UK is unevenly spread.. Based on the Royal College of
21
22 255 Radiologists definition of 'supportive' IO[1], this encompasses many routine procedures that can be
23
24 256 carried out by diagnostic radiologists which is reflected in the excellent availability of these
25
26 257 procedures throughout the UK. Beyond basic image-guided drainage procedures, the provision of
27
28 258 specialist vascular, gastro-intestinal or biliary 'symptomatic' intervention is less routinely available
29
30 259 apart from in the larger tertiary centers which were also providing disease-modifying IO. This
31
32 260 highlights important areas to target nationally for radiology and IO training.
33

34 261

35
36 262 Given the vital role of IR in the management of critically ill patients, the comprehensive provision of
37
38 263 supportive IO in most parts of the UK reflects the drive to train more radiologists with basic
39
40 264 interventional skills, which are also transferrable to IO[6]. Only 1 trust without an IR department
41
42 265 offered IO. We were unable to capture if most of the IO procedures were done by the IR
43
44 266 department or not, with institutions occasionally splitting non-vascular (e.g. ablation) and vascular
45
46 267 interventions (e.g. transarterial chemoembolization - TACE) between the diagnostic radiologists
47
48 268 and the interventional radiologists who also have to cover the on-call service for non-oncology
49
50 269 related emergency procedures such as trauma, bleeding or aortic syndromes. A major recruitment
51
52 270 drive currently is the provision of on-call IR services and given the overlap between IO and IR
53
54 271 training, emergency IR provision is therefore linked with the provision of IO services not only for
55
56 272 maintaining the availability of supportive services in small district hospitals but also for the
57
58 273 provision of disease-modifying IO in specialist centres. Additional need for interventional
59
60

1
2 274 radiographers and nursing cover for IO services should not be overlooked either to allow a new IO
3
4 275 service to be introduced.
5
6 276
7
8 277 We acknowledge that disease-modifying treatments form a smaller proportion of IO workload and
9
10 278 centralization of this is happening as part of the current NHS model for cancer services[7]. One
11
12 279 argument for this model in the context of IO is to ensure that more complex IO procedures are
13
14 280 undertaken by those who carry out a sufficient number of cases to maintain competency however
15
16 281 this should not preclude suitable patients from being referred due to their geographic location.
17
18 282 There are NHS trusts/ boards, most noticeably in rural Scotland and Northern Ireland where
19
20 283 access to disease-modifying IO services appears limited and linking up with neighboring hospitals
21
22 284 to set up formal referral pathways should be considered. What also remains unclear is what the
23
24 285 current demand for IO services are generally but particularly in these rural regions, as we have no
25
26 286 data to suggest current arrangements are sub-optimal. It would not be necessary or appropriate for
27
28 287 all providers to liaise with IO services, and these should be facilitated through regional cancer
29
30 288 networks with more integrated pathways of care[7]. Currently there appears to be 136 out of 153
31
32 289 acute NHS trusts in England, which are listed to offer acute oncology services[8]. Further work is
33
34 290 required to elucidate whether there is any discrepancy in the regional demand and supply of
35
36 291 disease-modifying IO.
37
38 292
39
40 293 The perceived barriers to starting up elective disease-modifying services stemmed from shortfalls
41
42 294 in funding, staffing and support from other specialties. With tertiary centres undertaking much
43
44 295 higher volumes of disease modifying IO procedures, some smaller district general hospitals felt
45
46 296 unsupported in starting up their own service, from financial considerations when purchasing the
47
48 297 equipment to garnering support from allied specialties such as surgery and oncology. This is an
49
50 298 important point as it highlights the need for greater awareness of the role of the interventional
51
52 299 radiologist in oncology care and we must strive to work even closer with oncologists given the new
53
54 300 evidence suggesting the added value of combination therapies and incorporation of IO procedures
55
56 301 into European cancer guidelines[9]. However, with the current model of centralizing cancer
57
58 302 services, these barriers would only be an issue if cancer centers were unable to provide IO. To
59
60

1
2 303 improve patient selection for complex IO procedures, interventional radiologists should have a
3
4 304 regular role in multi-disciplinary team meetings. With only 19 institutions (11%) currently having a
5
6 305 formal IO lead clinician, there is a role for dispersed leadership to achieve structural change in
7
8 306 established cancer networks.

9
10 307

11 308 Local expertise and facilities help determine the IO that is offered. An example is the provision of
12
13 309 disease-modifying IO for the liver, which is centred around the national liver transplant units[10].

14 310 Clearly image-guided tumour ablation, TACE and SIRT are effective therapies than can be used
15
16 311 solely or in combination with chemotherapy or surgery to improve the outcome of such patients.

17
18 312 [11 12]. Participation in MDT discussions will also allow interventional radiologists and radiologists

19
20 313 familiar with IO Techniques to educate other clinicians on the role of IO in the management of

21
22 314 patients and contribute towards improvement and restructuring of services. This will also open

23
24 315 opportunities to undertake collaborative research that will be higher impact and wider reaching to

25
26 316 the oncology community.

27
28 317

29
30 318 The recurrent issue of lack of staffing within IR remains a barrier. Despite the promising provision

31
32 319 of supportive IO, most departments are struggling to cope with the demand for basic vascular,

33
34 320 urological and biliary procedures, necessary to provide a sustainable out of hours service, without

35
36 321 compounding this with additional workload and need for additional training for disease-modifying

37
38 322 IO.

39
40 323

41
42 324 Changes to the delivery of healthcare throughout the UK demands that IO treatments can

43
44 325 demonstrate not only a therapeutic benefit but also cost-effectiveness. For units with a referral

45
46 326 pathway for disease-modifying IO, there was a common theme that this set-up was more cost

47
48 327 effective than starting a service from scratch. Without knowledge of the actual demand for these IO

49
50 328 procedures, there is no answer to this currently, and clinical investigators must incorporate

51
52 329 measures of cost-effectiveness and patient-reported outcomes into large-scale studies to provide

53
54 330 more robust evidence[13]. Even if these IO treatments can be shown to be equally effective

55
56 331 compared with the current standard of care but with significantly less morbidity, then it will allow

57
58
59
60

1
2 332 the specialty to develop further, however current studies have not offered definitive
3
4 333 conclusions[14]. Building upon the knowledge of these IO networks will allow better registry data
5
6 334 that can be used to derive larger cohorts for future trials and also commissioning of new services.
7

8 335

9
10 336 The limitations of the present study include those inherent in the survey/ questionnaire format such
11
12 337 as the subjective element depending on whether a superintendent radiographer or consultant
13
14 338 radiologist responded given their underlying experience and knowledge of their radiology services
15
16 339 which could impact on the detail of their survey answers. The strengths of the survey include 100%
17
18 340 response rate from 179 acute NHS trusts/ health boards which allowed a comprehensive map of
19
20 341 both supportive and disease-modifying IO procedures offered in the UK that will help direct
21
22 342 radiology/IO training, future planning of new IO services and allow for more integrated cancer
23
24 343 pathways.
25

26 344

27 28 345 **Conclusion**

29
30 346 The provision of IO services in the UK is promising however collaboration and networking is
31
32 347 necessary to ensure disease-modifying IO procedures are made accessible to all patients
33
34 348 throughout the UK and to facilitate improved registry data collection for research and
35
36 349 commissioning or funding of new services.
37

38 350

39
40 351
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 352

2 353

3
4
5 354 All authors have completed the ICMJE uniform disclosure form at
6
7
8 355 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted
9
10 356 work; no financial relationships with any organisations that might have an interest in the submitted
11
12 357 work in the previous three years; no other relationships or activities that could appear to have
13
14 358 influenced the submitted work

15 359

16
17
18 360 Transparency declaration: I affirm that the manuscript is an honest, accurate, and transparent
19
20 361 account of the study being reported; that no important aspects of the study have been omitted; and
21
22 362 that any discrepancies from the study as planned (and, if relevant, registered) have been
23
24 363 explained.

25 364

26
27
28 365 Data sharing: no additional data available.

29 366

367 **References**

- 368 1. NHS England Department of Health and Public Health England. Progress in improving cancer
369 services and outcomes in England. 2015.
- 370 2. NHS England. Achieving World-Class Cancer Outcomes: Taking the strategy forward. 2016
- 371 3. Royal College of Radiologists. Interventional oncology: guidance for service delivery. 2013.
372 http://www.rcr.ac.uk/sites/default/files/publication/RCR%2813%29_IO_0.pdf. (accessed 6th
373 June 2016)
- 374 4. Centre for Workforce Intelligence. Securing the future workforce supply: clinical radiology
375 stocktake. In: London: Centre for Workforce Intelligence. 2012.
- 376 5. UK Government. Transparency data NHS foundation trust directory. 2015.
377 [https://http://www.gov.uk/government/publications/nhs-foundation-trust-directory/nhs-
378 foundation-trust-directory](https://http://www.gov.uk/government/publications/nhs-foundation-trust-directory/nhs-
378 foundation-trust-directory). (accessed 6th June 2016)
- 379 6. Royal College of Radiologists. Provision of Interventional Radiology Services. 2013.
380 [https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR\(14\)12_POI
381 R.pdf](https://http://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR(14)12_POI
381 R.pdf). (accessed 6th June 2016)
- 382 7. Independent Cancer Taskforce Cancer Research UK. Achieving World-Class Cancer
383 Outcomes, A strategy for England 2015-2020. 2015
- 384 8. National Peer Review Programme. My Cancer Treatment. 2016.
385 <http://www.mycancertreatment.nhs.uk/find-your-treatment/>. (accessed 6th June 2016)
- 386 9. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice
387 Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the
388 European Society for Medical Oncology / ESMO 2016;**27**(suppl 5):v58-v68 doi:
389 10.1093/annonc/mdw328[published Online First: Epub Date]].
- 390 10. NHS Blood and Transplant. Transplant Units in the UK. Secondary Transplant Units in the UK.
391 2016. <http://www.odt.nhs.uk/transplantation/transplant-units-in-uk/>. (accessed 6th June
392 2016)
- 393 11. Hickey R, Vouche M, Sze DY, et al. Cancer Concepts and Principles: Primer for the
394 Interventional Oncologist-Part I. Journal of Vascular and Interventional Radiology
395 2013;**24**(8):1157-64 doi: 10.1016/j.jvir.2013.04.024[published Online First: Epub Date]].

- 1
2 396 12. Hickey R, Vouche M, Sze DY, et al. Cancer Concepts and Principles: Primer for the
3
4 397 Interventional Oncologist-Part II. Journal of Vascular and Interventional Radiology
5
6 398 2013;**24**(8):1167-88 doi: 10.1016/j.jvir.2013.04.023[published Online First: Epub Date]].
7
8 399 13. Franklin JM, GebSKI V, Poston GJ, et al. Clinical trials of interventional oncology-moving from
9
10 400 efficacy to outcomes. Nature reviews. Clinical oncology 2015;**12**(2):93-104 doi:
11
12 401 10.1038/nrclinonc.2014.199[published Online First: Epub Date]].
13
14 402 14. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014
15
16 403 update. European urology 2015;**67**(5):913-24 doi: 10.1016/j.eururo.2015.01.005[published
17
18 404 Online First: Epub Date]].
19
20 405
21 406
22
23 407
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 408 **Figure Legends:**

3
4 409 **Figure 1:** UK Map showing the overall provision of interventional oncology (IO) services
5
6 410 throughout the UK.

7
8 411 **Figure 2:** Middle pie chart (A) displaying total number/percentage of trusts which offer IO or have a
9
10 412 referral pathway, number which plan to set up IO service or referral pathway in the next 12 months
11
12 413 (All English trusts) and those without any plans to set up a IO service pathway. The top (B) and
13
14 414 bottom (C) pie charts display the breakdown of healthcare trusts/ health boards by country.

15
16 415 **Figure 3:** UK Map showing what types of IO procedures (supportive and/ or disease modifying
17
18 416 procedures) are undertaken in each NHS trust/ health board.

19
20 417 **Figure 4:** UK Map showing the provision of ablation services: (A) Renal ablation (B) Liver ablation
21
22 418 (C) Bone ablation and (D) Lung ablation.

23
24 419 **Figure 5:** UK Map showing the provision of (A) Trans-arterial chemoembolization (TACE) and (B)
25
26 420 Selective internal radiation therapy (SIRT).

27
28 421

29
30 422

31
32 423

33
34 424

35
36 425

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

426 **Table Legends**

427 **Table 1:** Type of supportive/ symptomatic IO procedure and number of trusts that offer each and
 428 percentage of total number of trusts that provided information on the types of procedure offered
 429 (n=137). 7 out of 144 who offered IO did not include what procedures were offered and were
 430 excluded from calculations.

Type of supportive/ symptomatic IO procedure	Number of trusts	Percentage of total (%)
Image-guided biopsy	137	100
Nephrostomy	129	94
Image-guided drainage	128	93
Central venous catheter	125	91
Ureteric stenting	124	91
Biliary drainage and stenting	118	86
Vena caval filtration	88	64
Gastrointestinal stenting	87	64
Percutaneous Trans-hepatic Cholangiography (PTC)	84	61
Enteral tube placement e.g. Radiologically Inserted Gastrostomy (RIG)	81	59
Vena caval stenting	79	58
Ascitic diversion	39	28
Vertebroplasty	6	4
Isolated perfusion chemotherapy	5	4

431

432 **Table 2:** Type of disease-modifying IO procedures and number of trusts that offer each and
 433 percentage of total number of trusts (n=179).

Type of disease-modifying IO procedure	Number of trusts	Percentage (%)
Trans-arterial chemoembolization (TACE)	40	22
Liver ablation	39	22
Kidney ablation	39	22
Lung ablation	28	16
Bone ablation	18	10
Selective Internal Radiation Therapy (SIRT)	17	9
Prostate ablation	2	1

434

435

436

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1: UK Map showing the overall provision of interventional oncology (IO) services throughout the UK.

94x127mm (300 x 300 DPI)




Figure 2: Middle pie chart (A) displaying total number/percentage of trusts which offer IO or have a referral pathway, number which plan to set up IO service or referral pathway in the next 12 months (All English trusts) and those without any plans to set up a IO service pathway. The top (B) and bottom (C) pie charts display the breakdown of healthcare trusts/ health boards by country.

196x187mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: UK Map showing what types of IO procedures (supportive and/ or disease modifying procedures) are undertaken in each NHS trust/ health board.

118x157mm (300 x 300 DPI)



Figure 4: UK Map showing the provision of ablation services: (A) Renal ablation (B) Liver ablation (C) Bone ablation and (D) Lung ablation.

230x299mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 5: UK Map showing the provision of (A) Trans-arterial chemoembolization (TACE) and (B) Selective internal radiation therapy (SIRT).

259x169mm (300 x 300 DPI)

view only

Cross-sectional Study of the Provision of Interventional Oncology Services in the United Kingdom

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page in Manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	13
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8

		(b) Indicate number of participants with missing data for each variable of interest	n/a
Outcome data	15*	Report numbers of outcome events or summary measures	8-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	n/a
		(b) Report category boundaries when continuous variables were categorized	8-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-10
Discussion			
Key results	18	Summarise key results with reference to study objectives	10-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.